Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-18 (benzinga.com)
Deal Dispatch: Biden Punts TikTok Ban To Trump, Fate Hangs — Another Private Equity Owned Retailer Goes Bankrupt - AbbVie (NYSE:ABBV), Biogen (NASDAQ:BIIB) -
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Read more
2024-12-10 (nikkeibp.co.jp)
Biogen's financial results for fiscal year 2023:
Biogen continues to struggle with the release of generic products for its main products and has been unable to make a comeback in fiscal 2023. Revenue decreased 3.3% from the same period last year to $9,836.4 million (1,381.8 billion yen, annual average exchange rate: $1 = 140.49 yen), the fourth consecutive quarterly decline in revenue. , finally 10 billion It broke through the dollar mark. Even on a constant exchange rate (CER) basis, which assumes that the converted exchange rate is the same as in the same period last year, sales were down 1%.
Read more
2024-09-26 (stocknews.com)
BIIB: 3 Biotech Stocks Wall Street Predicts Will Skyrocket
Biogen Inc.(NASDAQ:BIIB): Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen( BIIB), Royalty Pharma( RPRX), and BioMarin
Read more
2024-08-01 (optionfinance.fr)
Biogen raises its financial forecasts for 2024
(AOF) - Biogen's revenues in the second quarter of 2024 increase by 1% to $2.47 billion. Over this period, its adjusted EPS (non-GAAP) was $5.28, an increase of 31%. The biotechnology company raises its adjusted EPS target range for the year 2024: between 15.7
Read more
2024-07-01 (tijd.be)
Biogen faces possible share price breakout
Biogen halted its downward trend in recent months after a head-and-shoulder reversal. In recent weeks, the share has held up well above the negative trend
Read more
2024-01-10 (boerse-express.com)
Biogen share: price decline despite stable financial situation
Biogen shares recorded a slight decline of 0.25% to EUR 169.38 on October 10, 2024. Despite this short-term weakness, the company shows a solid financial foundation. With a market capitalization of EUR 24.6 billion, Biogen remains a heavyweight in the biotechnology industry.
Read more
2023-11-14 (finmarket.ru)
Investbank
Investment bank ``Sinara'' maintains ``hold'' rating for Tesla shares with outlook
Read more
2023-10-17 (pionline.com)
Companies move to settle ERISA lawsuits in third quarter
During the third quarter of 2023, 58 ERISA-related lawsuits were filed and/or updated. Each event represents the involved parties either reaching a settlement or filing an appeal, or a court decision was made.
Read more
2023-09-01 (finmarket.ru)
The CBR rate may drop to 13% in 3Q24 -
The Bank of Russia will begin to soften its rhetoric, most likely from the third quarter of next year, and the key
Read more
2023-06-30 (bloomberglaw.com)
Details in Biogen Loss to Novartis Signal Trouble for Drugmakers
Biogen Inc. failed to show it’d be irreparably harmed if Novartis AG’s Sandoz Inc. wasn’t blocked from launching its biosimilar of Tysabri while a patent-infringement suit over the blockbuster multiple sclerosis treatment continues, a redacted ruling reveals.
Read more
2023-06-19 (sharewise.com)
Does This Signal Trouble for Biogen
Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug
Read more
2022-09-29 (e-fundresearch.com)
Lumyna - American Debt - Credit UCITS Fund
Fund Rankings & Insights - Lumyna American Dbt Crdt UCITS USD B Inc (LU2479960952) - Lumyna Investments Limited - other bond funds and global corporate bonds (USD-hedged) funds in the fund ranking on e-fundresearch.com
Read more